UniQure (QURE) stock drop looms as FDA concern over Huntington’s data spurs Mizuho downgrade and delayed launch
I'm PortAI, I can summarize articles.
UniQure's stock faces a potential drop as Mizuho downgrades its price target from $60 to $33, citing FDA concerns over Huntington’s data. Despite the downgrade, the analyst maintains an Outperform rating, expecting the stock to double by 2026. The financial model for AMT-130 was adjusted following FDA communication.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments